Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone...

29
Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: [email protected]

Transcript of Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone...

Page 1: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Sympathomimetics

Ed Bilsky, Ph.D.Department of PharmacologyUniversity of New England

Phone 283-0170, x2707

E-mail: [email protected]

Page 2: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Fight or Flight????

Page 3: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.
Page 4: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Drugs that Increase Adrenergic Activity

Direct acting sympathomimetics– alpha-1 agonists (phenylephrine)– alpha-2 agonists (clonidine)– beta-1 agonists (dobutamine)– beta-2 agonists (albuterol)

Indirect acting sympathomimetics– promote release (amphetamine)– block reuptake (cocaine)

Page 5: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Synthesis of Catecholamine Neurotransmitters

HO CH2 C

H

NH3+

COO-

HO CH2 C

H

N H3+

COO-

HO

HO CH2 CH2

N H3+

H O

Tyrosine

Tyrosine Hydroxylase

Dopamine

L-DOPA

DOPA Decarboxylase

HO CH CH2

N H3+

H O

OH

Norepinephrine

Dopamine--Hydroxylase

Page 6: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Sympathomimetics

Structure:

• The structure of many sympathomimetics is based on the phenylethylamine structure and the catechol nucleus

• Modifications of the structure have significant effects on pharmacodynamics– changes in affinity and selectivity for adrenergic receptors– changes in efficacy (agonist versus antagonist)

• Changes in the chemical structure also alter the pharmacokinetic profile of the compound

Page 7: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Pharmacodynamics:

• Adrenergic receptors belong to the super family of G-protein coupled receptors– Gs - stimulates adenylyl cyclase --> increases cAMP– Gi - inhibits adenylyl cyclase --> decreases cAMP– Gq - activates phospholipase C --> increases IP3 and DAG

• Each type of receptor has a specific coupling mechanism– Alpha-1 receptors: Gq --> increased calcium– Alpha-2 receptors: Gi --> activate K+ and blocks Ca2+ channels– beta receptors: Gs --> various effect (e.g., increased cardiac

contractility, smooth muscle relaxation, increased glycogen phosphorylase activity)

Sympathomimetics

Page 8: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Pharmacodynamics:

• Adrenergic receptors are under dynamic regulation that is affected by neurotransmitter activity, exogenous drugs, disease states and age– important clinical consequences are now being realized

• Desensitization of receptors can occur through a variety of mechanisms– transcription/translation of receptors– phosphorylation of receptors– internalization of receptors and decoupling with G-proteins– constitutive activity

Sympathomimetics

Page 9: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Organ System Effects

Cardiovascular system:

• Adrenergic receptors have major effects on arterial resistance (blood pressure/flow) and venous capacitance– alpha-1: vasoconstriction (skin and splanchnic vessels)– beta-2: vasodilation (skeletal muscle)– dopamine: vasodilation (renal, splanchnic, coronary and

cerebral vessels)

• Direct effects on the heart are primarily mediated by beta-1 receptors– positive chronotropic, dromotropic and inotropic effects– leads to an increase in cardiac output

Page 10: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Organ System Effects

Cardiovascular system (continued):

• Reflexes can alter the blood pressure response seen with drugs in healthy individuals– alpha agonist effects would be opposed by barroreceptor

reflexes that slow the heart– in hypotensive states, these drugs can bring blood pressure

back to normal– beta agonist effects on the heart would be countered by

decreased resistance in some vascular beds

• Drugs that increase both alpha and beta activity (amphetamines) can produce dramatic increases in blood pressure

Page 11: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Organ System Effects

GI tract:

• Alpha and beta receptors produce relaxation of GI smooth muscle --> decreases motility

GU tract:

• Beta agonists relax uterine smooth muscle

• Alpha receptors regulate sphincter tone of the bladder which promotes continence

Exocrine glands:

• Increased sweat production in apocrine glands that respond to stress

Page 12: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Organ System Effects

Eye:

• Activation of alpha receptors produces mydriasis

• Alpha agonists increase aqueous humor outflow while beta antagonists decrease aqueous humor production

Respiratory tract:

• Beta-2 receptors mediate relaxation of bronchial smooth muscle (treatment of asthma)

• alpha-1 agonists produce vasoconstriction in vessels of the upper respiratory tract mucosa

Page 13: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Organ System Effects

Metabolic effects:

• Activation of the sympathetic nervous system increases lipolysis and glycogenolysis

CNS effects:

• Moderate doses of sympathomimetics can increase alertness, reduce fatigue and produce euphoria

• Higher doses can cause irritability, nervousness and psychotic reactions

Page 14: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Therapeutic Applications

Increased blood flow/pressure:

• Hypotension can occur in response to a number of different conditions– decreased blood volume, cardiac insufficiency, neurological

disease/trauma, infection, adverse drug reactions, etc.

• Sympathomimetics may be used in certain hypotensive emergencies (e.g., shock) to maintain adequate coronary and cerebral blood flow– volume replacement and treatment of the underlying cause

are the mainstays of therapy– use in treating anaphylactic shock (s.c. epinephrine)

• Oral ephedrine is used for the treatment of chronic orthostatic hypotension

Page 15: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Therapeutic Applications

Decreased blood flow/pressure:

• Reduction of regional blood flow can be accomplished with sympathomimetics– hemostasis during surgery– reduction of local anesthetic diffusion– prolongation of local anesthetic duration of action– reduction of mucous membrane congestion

• The unique properties of cocaine (local anesthetic and sympathomimetic) make it a valuable drug in certain types of surgery– facial, oral or nasopharyngeal

Page 16: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Therapeutic Applications

Cardiac applications:

• Alpha agonists used to be used for paroxysmal atrial tachycardia– safer alternatives such as verapamil, adenosine and

electrical cardioversion are now preferred

• Cardiac arrest can be treated with epinephrine, though electronic pacemakers are safer and more effective in heart block

• Beta-1 agonists are still used to increase cardiac output in congestive heart failure– problems with desensitization and toxicity with chronic

therapy

Page 17: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Therapeutic Applications

CNS effects:

• Sympathomimetics such as amphetamine have medical and non-medical uses:– increase level of alertness and reduction in boredom– elevation in mood– suppression of appetite– treatment of narcolepsy– treatment of ADHD

• There are problems with the abuse potential and toxicity of this class of agents

Page 18: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Therapeutic Applications

Respiratory applications:

• Beta-2 agonists remain a mainstay for treating asthma– other beneficial effects besides bronchodilation

Other applications:

• Phenylephrine used to produce mydriasis and as a decongestant for minor allergic hyperemia of the conjunctival membranes

• Glaucoma responds well to alpha agonists and beta antagonists

• Questionable efficacy of beta agonists for suppressing premature labor

Page 19: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Sympatholytics

Ed Bilsky, Ph.D.Department of PharmacologyUniversity of New England

Phone 283-0170, x2707

E-mail: [email protected]

Page 20: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Drugs that Decrease Adrenergic Activity

Direct acting sympatholytics– reversible alpha antagonists (phentolamine,

prazosin)– irreversible alpha antagonist (phenoxybenzamine)– nonselective beta antagonist (propranolol)– selective beta-1 antagonist (metoprolol)

Indirect acting sympatholytics– decrease storage (reserpine)

Page 21: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Pharmacokinetics:

• The oral bioavailability and biodistribution of these compounds can vary, though in general, these compounds are given p.o.

• The half-life of these agents varies considerably– esmolol-ultrashort acting beta blocker (t1/2=10 min)

– propranolol-nonselective beta blocker (t1/2=3-6 hrs)

– atenolol-nonselective beta blocker (t1/2=6-9 hrs)

– nadolol- nonselective beta blocker (t1/2=14-24 hrs)

Sympatholytics

Page 22: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Pharmacodynamics:

• Two major classes of agents for the alpha blockers– reversible (phentolamine)– irreversible (phenoxybenzamine)

• Beta blockers are typically reversible antagonists

• The selectivity and efficacy of these drugs varies considerably– phentolamine is considered a dirty drug due to affinity at

alpha-1 and 2, histamine, muscarinic and serotonin receptors– carvedilol has affinity for both alpha and beta receptors– beta blocker selectivity (propranolol vs metoprolol)– pure antagonists versus partial agonists (metoprolol vs

pindolol)

Sympatholytics

Page 23: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Organ System Effects: Alpha Blockers

Cardiovascular system:

• Major effects on arteriolar and venous tone– alpha antagonists produce vasodilation by relaxing smooth

muscle– decreased vascular resistance and a fall in blood pressure

• The alpha blockers can produce postural hypotension and reflex tachycardia

Other effects:

• Alpha blockers can produce miosis and nasal stuffiness

Page 24: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Therapeutic Applications: Alpha Blockers

Pheochromocytoma:

• Typically caused by a tumor in the adrenal medulla that releases large amounts of epinephrine and norepinephrine– hypertension, tachycardia, arrhythmias

• Alpha-antagonists (phenoxybenzamine) can be used in the management of this disease– used in preoperative care and for patients that have inoperable

tumors

Hypertension:

• Prazosin is a tertiary drug for treatment of hypertension

Hypertensive emergencies:

• Limited applications for management of hypertensive emergencies– other drugs are preferred in the management of this condition

Page 25: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Organ System Effects: Beta Blockers

Cardiovascular system:

• Primary effect is on cardiac beta-1 receptors

• Beta antagonists produce negative chronotropic, inotropic and dromotropic effects– reduction in blood pressure

• Other effects include an inhibition of renin release which contributes to the antihypertensive actions

Respiratory system:

• Nonselective blockade of beta-2 receptors may increase airway resistance, especially in asthmatics

Page 26: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Organ System Effects: Beta Blockers

Other effects:

• Blockade of beta receptors in the CNS may produce changes in mood and wakefulness

• Several beta blockers reduce intraocular pressure by decreasing aqueous humor production

• Metabolic effects on lipid and carbohydrate metabolism may occur– complications in insulin-dependent diabetic patients– elevations of VLDL and decreases in HDL cholesterol

• Some beta blockers have local anesthetic actions– probably not of clinical significance

Page 27: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Therapeutic Applications: Beta Blockers

Hypertension:

• Beta blockers are one of the primary drugs used in the management of hypertension– safe, well tolerated and effective in reducing morbidity and

mortality

Angina:

• Beta blockers can be used prophylactic for the treatment of angina– decreased cardiac oxygen demand

Cardiac arrhythmias:

• Beta blockers are effective for treating some supraventricular and ventricular arrhythmias– particularly effective when the arrhythmia is caused by excessive

sympathetic tone

Page 28: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Therapeutic Applications: Beta Blockers

Congestive heart failure:

• There is some clinical evidence that beta-blockers can decrease morbidity in congestive heart failure– need to assess sympathetic compensation for cardiac output– possibly reduces aspects of cardiac remodeling and oxidative

stress

CNS diseases:

• Utility in treating some forms of migraine headache, tremor and anxiety

Glaucoma:

• Beta blockers decrease production of aqueous humor and intraocular pressure– eye drops available

Page 29: Sympathomimetics Ed Bilsky, Ph.D. Department of Pharmacology University of New England Phone 283-0170, x2707 E-mail: ebilsky@une.edu.

Side-Effects: Beta Blockers

• Beta blockers are typically well tolerated with serious side-effects being rare

• Some occurrence of drug allergies (rash, fever, etc.)

• CNS effects can include sedation, sleep disturbances and depression– advantage of more water soluble compounds?

• Beta blocker should not be withdrawn abruptly in patients being treated for hypertension

• Exacerbation of disease symptoms possible in asthmatics with all beta blockers

• Increased hypoglycemic episodes might be possible– avoid their use in insulin-dependent diabetics